Ferroptosis-centered Drug Response Information
General Information of the Drug (ID: ferrodrug0294)
| Name |
Ginsenoside Rh4
|
||||
|---|---|---|---|---|---|
| Synonyms |
Ginsenoside Rh4; 174721-08-5; Ginsenoside Rh(4); (2R,3R,4S,5S,6R)-2-[[(3S,5R,6S,8R,9R,10R,12R,13R,14R,17S)-3,12-dihydroxy-4,4,8,10,14-pentamethyl-17-[(2E)-6-methylhepta-2,5-dien-2-yl]-2,3,5,6,7,9,11,12,13,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-6-yl]oxy]-6-(hydroxymethyl)oxane-3,4,5-triol; CHEMBL504029; CHEBI:176255; DTXSID001317113; HY-N0905; MFCD22125012; AKOS030526659; CS-3843; FS-7833; NCGC00485965-01; AC-34672
Click to Show/Hide
|
||||
| Structure |
 |
||||
| Formula |
C36H60O8
|
||||
| IUPAC Name |
(2R,3R,4S,5S,6R)-2-[[(3S,5R,6S,8R,9R,10R,12R,13R,14R,17S)-3,12-dihydroxy-4,4,8,10,14-pentamethyl-17-[(2E)-6-methylhepta-2,5-dien-2-yl]-2,3,5,6,7,9,11,12,13,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-6-yl]oxy]-6-(hydroxymethyl)oxane-3,4,5-triol
|
||||
| Canonical SMILES |
CC(=CCC=C(C)C1CCC2(C1C(CC3C2(CC(C4C3(CCC(C4(C)C)O)C)OC5C(C(C(C(O5)CO)O)O)O)C)O)C)C
|
||||
| InChI |
InChI=1S/C36H60O8/c1-19(2)10-9-11-20(3)21-12-15-35(7)27(21)22(38)16-25-34(6)14-13-26(39)33(4,5)31(34)23(17-36(25,35)8)43-32-30(42)29(41)28(40)24(18-37)44-32/h10-11,21-32,37-42H,9,12-18H2,1-8H3/b20-11+/t21-,22-,23+,24-,25-,26+,27+,28-,29+,30-,31+,32-,34-,35-,36-/m1/s1
|
||||
| InChIKey |
OZTXYFOXQFKYRP-TXRYYSRHSA-N
|
||||
| PubChem CID | |||||
Full List of Ferroptosis Target Related to This Drug
Unspecific Target
| In total 1 item(s) under this Target | ||||
| Experiment 1 Reporting the Ferroptosis-centered Drug Act on This Target | [1] | |||
| Responsed Disease | Multiple myeloma | ICD-11: 2A83 | ||
| Responsed Regulator | NAD-dependent protein deacetylase sirtuin-2 (SIRT2) | Suppressor | ||
| Pathway Response | Fatty acid metabolism | hsa01212 | ||
| Ferroptosis | hsa04216 | |||
| Apoptosis | hsa04210 | |||
| Cell Process | Cell ferroptosis | |||
| Cell proliferation | ||||
| Cell apoptosis | ||||
| Cell cycle | ||||
| In Vitro Model | NCI-H929 cells | Plasma cell myeloma | Homo sapiens | CVCL_1600 |
| Response regulation | Ginsenoside Rh4 inhibited SIRT2 expression in multiple myeloma (MM) cells. The overexpression of SIRT2 reversed the effects of ginsenoside Rh4 on cell proliferation, cell apoptosis, cycle arrest and ferroptosis in MM. Overall, ginsenoside Rh4 inhibited the malignant progression of MM and induced ferroptosis by regulating SIRT2. | |||